Sunshine Biopharma Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228.4K | $71.4K | $21.1K | $0 |
| Cost of Revenue | $24.1M | $24.2M | $15.8M | $2.6M | $117.8K | $25.8K | $11.1K | $0 |
| Gross Profit | $12.3M | $10.7M | $8.3M | $1.7M | $110.6K | $45.6K | $10.1K | $0 |
| Gross Margin | 33.8% | 30.6% | 34.6% | 39.0% | 48.4% | 63.8% | 47.7% | — |
| Operating Expenses | ||||||||
| Research & Development | $604.3K | $933.9K | $1.9M | $811.9K | $672.2K | $1.7K | $15.2K | $12.8K |
| SG&A Expense | $18.5M | $16.5M | $13.1M | $28.7M | $2.6M | $622.4K | $651.7K | $1.2M |
| Operating Income | $-6.2M | $-5.8M | $-4.8M | $-27.0M | $-2.4M | $-576.9K | $-641.6K | $-1.2M |
| Operating Margin | -17.2% | -16.7% | -19.9% | -621.3% | -1,068.2% | -807.8% | -3,037.9% | — |
| Interest Expense | — | — | $137.3K | $39.4K | $328.8K | $168.1K | $115.9K | $143.5K |
| Pretax Income | $-6.0M | $-5.4M | $-4.1M | $-26.5M | $-12.4M | — | — | — |
| Income Tax Expense | $21.6K | $-234.9K | $395.2K | $233.3K | $0 | $0 | — | — |
| Net Income | $-6.0M | $-5.1M | $-4.5M | $-26.7M | $-12.4M | $-2.8M | $-1.7M | $-2.2M |
| Net Margin | -16.5% | -14.7% | -18.7% | -615.4% | -5,444.4% | -3,898.7% | -7,860.9% | — |
| EPS (Basic) | $-1.44 | $-1.22 | $-58.56 | $-0.29 | $-0.13 | $-0.08 | $0.00 | $0.00 |
| EPS (Diluted) | — | $-1.22 | $-58.56 | $-0.29 | $-0.13 | — | — | — |
| Shares Outstanding (Basic) | 4.2M | 4.2M | 146.0M | 91.1M | 94.0M | 7.35B | 7.48B | 8.34B |
| Shares Outstanding (Diluted) | 4.2M | 4.2M | 146.0M | 91.1M | 94.0M | 7.35B | 7.48B | 8.34B |
| Dividends Per Share | — | — | — | — | — | — | — | — |